Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494206 · ClinicalTrials.gov registry record · NA
Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT02494206: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02494206 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02494206, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of QBX258, a compound developed by Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with stage I-II breast cancer related lymphedema.
Primary Outcome
Therapeutic volume changes in the arm will be calculated using the methods published by Anderson et al (2000).65 Briefly, the difference in volume measurements between the normal and lymphedematous arms at baseline (i.e volume excess) will be compared to the volume differential after drug treatment and following the washout period using the following formula: (VL-VN) B - (VL-VN) F
Interventions
- DRUG QBX258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-05 |
| Phase | NA |
What the finished NCT02494206 record still lists
NCT02494206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which QBX258 is the first listed.
NCT02494206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02494206 about?
NCT02494206 is a clinical study titled "Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)". The purpose of this study is to assess the efficacy of QBX258, a compound developed by Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with stage I-II breast cancer related lymphedema.
What is the current status of trial NCT02494206?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2015-07. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02494206?
The interventions under investigation include: QBX258 (DRUG).
Who is sponsoring clinical trial NCT02494206?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02494206's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia